Deerfield Management Company L.P. Series C Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Deerfield Management Company L.P. Series C bought a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 22,123 shares of the company’s stock, valued at approximately $173,000.

Several other institutional investors have also recently made changes to their positions in GDRX. Beacon Capital Management LLC purchased a new stake in GoodRx in the first quarter worth $28,000. Plato Investment Management Ltd bought a new stake in shares of GoodRx during the 2nd quarter valued at $43,000. Gerber LLC purchased a new stake in shares of GoodRx in the 4th quarter worth about $75,000. EntryPoint Capital LLC increased its stake in shares of GoodRx by 165.2% in the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after acquiring an additional 11,548 shares in the last quarter. Finally, Syon Capital LLC purchased a new position in GoodRx during the 4th quarter valued at about $168,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $6.85 on Friday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The firm’s 50-day moving average price is $7.81 and its 200-day moving average price is $7.57. GoodRx Holdings, Inc. has a 52-week low of $4.14 and a 52-week high of $9.26. The company has a market cap of $2.60 billion, a PE ratio of -684.32, a PEG ratio of 3.38 and a beta of 1.38.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $200.60 million during the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $0.02 EPS. As a group, analysts anticipate that GoodRx Holdings, Inc. will post 0.14 EPS for the current year.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.17% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on GDRX. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research note on Friday, August 9th. Citigroup lowered their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. UBS Group reduced their price target on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Finally, Morgan Stanley upped their price target on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.36.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.